Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks.

On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying out of pocket through telehealth partnerships.

Jonsson told Reuters the pharma firm will seek regulatory approvals before launch. It plans to expand its obesity plan for consumers through telehealth providers, e-commerce platforms, and direct-to-patient channels, applying lessons learned from its US launch.

He also said Eli Lilly and Company (NYSE:LLY) will continue pursuing public reimbursement where available. Nonetheless, there is uncertainty surrounding President Donald Trump’s “most-favoured-nation” drug pricing policy. Jonsson commented that “Our goal will still be public coverage, wherever possible,” and that the MFN framework “will play a role for all launches.”

Reuters reported that the “AI-powered healthcare company” signed a deal with the Trump administration last year. It is committed to providing MFN pricing for new medicines. The firm also plans to go after reimbursed prices consistent with its interpretation of the policy.

Eli Lilly and Company (NYSE:LLY) works in the discovery, development, manufacture, and sale of pharmaceutical products. The company’s products include diabetes, oncology, immunology, neuroscience, and other products and therapies.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.